Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality.
COVID-19
FGF-2
PlGF
angiogenesis
mortality
placental growth factor
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
17
02
2021
received:
23
12
2020
accepted:
25
03
2021
pubmed:
9
4
2021
medline:
1
7
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury. To correlate circulating angiogenic markers vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF), and fibroblast growth factor 2 (FGF-2) to in-hospital mortality in COVID-19 adult patients. Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF, and FGF-2 were measured in each patient ≤48 h following admission. The study enrolled 237 patients with suspected COVID-19: 208 patients had a positive diagnostic for COVID-19, of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF, and FGF-2 significantly increase with the severity of the disease (P < .001). Using a logistic regression model, we found a significant association between the increase of FGF-2 or PlGF and mortality (odds ratio [OR] 1.11, 95% confidence interval [CI; 1.07-1.16], P < .001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], P < .001 for PlGF) while no association were found for VEGF-A levels. Receiver operating characteristic curve analysis was performed and we identified PlGF above 30 pg/ml as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curve (P = .001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer, and C-reactive protein (3.23 95% CI [1.29-8.11], P = .001). Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Sections du résumé
BACKGROUND
Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury.
OBJECTIVES
To correlate circulating angiogenic markers vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF), and fibroblast growth factor 2 (FGF-2) to in-hospital mortality in COVID-19 adult patients.
METHODS
Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF, and FGF-2 were measured in each patient ≤48 h following admission.
RESULTS
The study enrolled 237 patients with suspected COVID-19: 208 patients had a positive diagnostic for COVID-19, of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF, and FGF-2 significantly increase with the severity of the disease (P < .001). Using a logistic regression model, we found a significant association between the increase of FGF-2 or PlGF and mortality (odds ratio [OR] 1.11, 95% confidence interval [CI; 1.07-1.16], P < .001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], P < .001 for PlGF) while no association were found for VEGF-A levels. Receiver operating characteristic curve analysis was performed and we identified PlGF above 30 pg/ml as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curve (P = .001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer, and C-reactive protein (3.23 95% CI [1.29-8.11], P = .001).
CONCLUSION
Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Identifiants
pubmed: 33830623
doi: 10.1111/jth.15339
pmc: PMC8250221
pii: S1538-7836(22)01818-9
doi:
Substances chimiques
Biomarkers
0
Vascular Endothelial Growth Factor A
0
Placenta Growth Factor
144589-93-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1823-1830Subventions
Organisme : Agence Nationale de la Recherche / Fondation de France
ID : SARCODO
Organisme : Assistance Publique - Hôpitaux de Paris
ID : Mecenat COVID
Informations de copyright
© 2021 International Society on Thrombosis and Haemostasis.
Références
Am J Respir Crit Care Med. 2004 Jun 1;169(11):1203-8
pubmed: 14754760
J Thromb Haemost. 2020 Sep;18(9):2391-2399
pubmed: 32558198
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
Pulm Circ. 2020 Nov 25;10(4):2045894020966547
pubmed: 33282193
J Infect Dis. 2020 Nov 9;222(11):1789-1793
pubmed: 32812049
N Engl J Med. 2016 Jan 7;374(1):13-22
pubmed: 26735990
Eur Respir J. 2020 Mar 12;55(3):
pubmed: 31806721
Gut. 2005 May;54(5):666-72
pubmed: 15831913
JAMA. 2004 Jan 28;291(4):435-41
pubmed: 14747500
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
BJOG. 2020 Oct;127(11):1374-1380
pubmed: 32479682
Nat Med. 2001 May;7(5):575-83
pubmed: 11329059
Crit Care. 2020 Jun 23;24(1):373
pubmed: 32576222
Lupus. 2010 Jun;19(7):837-43
pubmed: 20133349
Angiogenesis. 2013 Jan;16(1):147-57
pubmed: 22983452
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Lancet Respir Med. 2020 Aug;8(8):807-815
pubmed: 32422178
Pathol Biol (Paris). 2014 Dec;62(6):391-4
pubmed: 25239280
Angiogenesis. 2021 Jan 15;:
pubmed: 33449299
Front Med (Lausanne). 2020 Nov 12;7:586307
pubmed: 33282891
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Stem Cell Rev Rep. 2021 Apr;17(2):694-699
pubmed: 32970229
Angiogenesis. 2021 Feb;24(1):145-157
pubmed: 33058027
Stem Cell Rev Rep. 2021 Feb;17(1):4-8
pubmed: 32399806
Angiogenesis. 2020 Nov;23(4):611-620
pubmed: 32458111
Angiogenesis. 2014 Jul;17(3):603-16
pubmed: 24419917
Angiogenesis. 2019 May;22(2):325-339
pubmed: 30607696